Programmed death 1 (PD‐1), programmed death‐ligand 1 (PD‐L1), and T‐cell lymphocyte antigen 4 (CTLA‐4) inhibitors have shown clinical activity and marked efficacy in the treatment of NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.